4 pharmaceutical companies related to collective procurement have been placed on the list of violations.

The National Drug Procurement Office issued an announcement canceling the qualification of Guangzhou Hiehe Pharmaceutical Co., Ltd.'s selection qualification for MesoBMO injection, and at the same time, this company and the entrusted manufacturing company, Chengdu Tiantaishan Pharmaceutical Co., Ltd., were included in the list of violations; canceling the selection qualifications of Beijing Fukang Ren Biological Pharmaceutical Technology Co., Ltd.'s Dopamine Hydrochloride Injection and Xi Delong Company's Dapagliflozin tablets, and at the same time, the two companies were included in the list of violations.